作为反击，8月11日晚间，*ST苏吴公告称，控股孙公司达透医疗就Regen违约事项向深圳国际仲裁院提 起仲裁，并于2025年8月7日获得深圳国际仲裁院受理立案。公司表示，若上述仲裁请求未得到支持，初 步索赔损失人民币16亿元，并保留根据案情进展及其他相关因素对前述索赔金额进行调整的权利。 同日晚间，*ST苏吴又通过官方公众号发布了《关于高举法律武器维护自身合法权益的严正宣告》，文 章通篇措辞激烈，用了"资本霸凌""强取豪夺""趁人之危"等词汇。 *ST苏吴还称："爱美客公司此举，已使得我司和达透公司陷入生死存亡的困境，也使得8万多中小投资 者利益严重损害，上千名员工生计悬于一线，千余家合作机构损失惨重。"（中国基金报） 【#童颜针代理权被撤销*ST苏吴索赔16亿#】7月18日，爱美客的子公司Regen向达透医疗发送了《解约 函》，要求撤销达透医疗作为AestheFill（即"童颜针"艾塑菲）产品在中国境内的独家经销商的所有相 关授权。一石激起千层浪。达透医疗为*ST苏吴的核心业务，消息一出，*ST苏吴股价连续跌停。 ...

Group 1 - The stock price of Langzi Co., Ltd. on August 6 was 17.78 yuan, a decrease of 0.03 yuan or 0.17% from the previous trading day [1] - The trading volume on that day was 53,422 hands, with a transaction amount of 95 million yuan [1] - The company’s main business includes clothing design, production, and sales, as well as involvement in medical beauty and cosmetics [1] Group 2 - As a listed company in Beijing, Langzi Co., Ltd. holds a certain influence in the textile and apparel industry [1] - On August 6, the net outflow of main funds for Langzi Co., Ltd. was 14.4672 million yuan, with a cumulative net outflow of 39.0282 million yuan over the past five trading days [1]

Group 1 - The medical beauty sector increased by 0.16% on August 6, with Jinbo Biological leading the gains [1] - The Shanghai Composite Index closed at 3633.99, up 0.45%, while the Shenzhen Component Index closed at 11177.78, up 0.64% [1] - Key stocks in the medical beauty sector showed varied performance, with Jinbo Biological closing at 328.28, up 0.90%, and Aimeike slightly down by 0.03% [1] Group 2 - The medical beauty sector experienced a net outflow of 171.11 thousand yuan from main funds, while retail funds saw a net outflow of 668.85 thousand yuan [1] - The table indicates that *ST Meigu had a main fund inflow of 145.78 thousand yuan but a significant outflow from retail investors [2] - Huaxi Biological and Aimeike also showed mixed fund flows, with Huaxi experiencing a net outflow from main funds and a small inflow from retail investors [2]

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Views - The company is expected to achieve a net profit of $13.4 to $14.8 million in H1 2025, representing a year-on-year growth of 538.1% to 604.8% [1] - The growth in net profit is primarily driven by a low base in H1 2024, continued growth in overseas markets, and lower investment and operating expenses [2] - The company has made a strategic investment in the orthodontic brand Shuyaki, acquiring a 35% stake to deepen its presence in emerging markets and enhance the penetration of invisible orthodontics [3] Financial Performance - The company’s revenue is projected to grow from $208 million in 2023 to $318 million in 2025, with year-on-year growth rates of 14.3% in 2023, 29.0% in 2024, and 18.1% in 2025 [5] - The net profit is expected to increase from $8 million in 2023 to $13 million in 2025, with growth rates of -75.4% in 2023, 60.4% in 2024, and 4.4% in 2025 [5] - The earnings per share (EPS) is forecasted to be $0.07 in 2025, with a price-to-earnings (P/E) ratio of 98.3 [5] Market Expansion - The company has established a localized development strategy, with significant growth in international cases, increasing from 33,000 in 2023 to 140,700 in 2024, a year-on-year increase of 326.4% [2] - The company is expanding its production capabilities in Brazil and is set to build a new manufacturing facility in Wisconsin, USA, which will be one of the most advanced centers for invisible orthodontics globally [2] Marketing Strategies - The company is actively enhancing its brand influence through diverse marketing strategies tailored to different city tiers, including collaborations with popular brands like My Little Pony and initiatives like the Angel KiD Star Plan [4]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002612 证券简称：朗姿股份 公告编号：2025-044 朗姿股份有限公司 关于公司和全资子公司融资相互提供担保并接受关联方担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1、朗姿股份有限公司（以下简称"朗姿股份"或"公司"）第五届董事会第二十九次会议和2024年度股东 大会分别审议通过了《关于2025年度对外担保额度的议案》，同意2025年度公司及其控股子公司的对外 担保总额不超过30.50亿元（以下除非特别注明，所称"元"均指"人民币元"），其中对资产负债率未超 过70%的控股子公司担保额度为24.00亿元，对资产负债率超过70%的控股子公司担保额度为6.50亿元。 该担保额度的有效期自公司2024年度股东大会审议批准本议案之日起至2025年度股东大会召开之日止。 截至本公告披露日，公司及控股子公司对外担保总余额为116,716万元，占公司2024年度经审计净资产 的41.87%；其中，实际被担保方北京莱茵服装有限公司资产负债率超过70%，公司对资产负债率超过 70%的 ...

Group 1 - The stock price of Sichuan Shuangma closed at 19.33 yuan on August 4, 2025, with a slight decrease of 0.02 yuan, representing a drop of 0.10% [1] - The company reported a trading volume of 1.58 billion yuan, with a fluctuation of 1.91% and a turnover rate of 1.08% on the same day [1] - Sichuan Shuangma's main business includes cement and building materials, while also venturing into biotechnology and medical aesthetics [1] Group 2 - The company aims to continuously promote the development of its core business and focus on high-growth industries such as biotechnology [1] - Sichuan Shuangma is seeking synergistic business opportunities to enhance its long-term competitiveness [1] - In investor interactions, the company expressed its commitment to optimizing its business layout and enhancing investor confidence through performance growth and development prospects [1] Group 3 - On August 4, the net inflow of main funds was 3.6693 million yuan, with a cumulative net inflow of 22.8371 million yuan over the past five days [1]

Core Points - From January 1, 2026, foreign tourists in South Korea will no longer be able to apply for tax refunds on medical beauty services, as the government has decided not to extend the special VAT refund policy for foreign tourists, which will officially expire on December 31 of this year [1] - The South Korean government implemented a temporary VAT refund policy for medical beauty services in April 2016 to promote high-value medical tourism related to the Korean Wave, allowing foreign tourists to claim a 10% VAT refund when receiving services at designated medical institutions [1] - In 2024, it is estimated that 1.17 million foreign patients will visit South Korea for medical treatment, with a total medical expenditure of 1.41 trillion KRW, averaging about 1.53 million KRW per person [1] - The medical beauty tax refund applications have reached 1.01 million, with a total refund amount of 95.5 billion KRW [1] - The medical and tourism industries in South Korea are calling for the government to extend the tax refund policy, as the "cost-performance" advantage of the medical beauty industry is seen as a core competitive strength to attract foreign visitors [1] Industry Concerns - There are concerns that the lack of institutional incentives may lead some institutions and customers to evade taxes through cash transactions, resulting in regulatory difficulties and transparency issues [2] - The Ministry of Health and Welfare plans to negotiate with tax authorities to seek an extension of the temporary policy, leaving room for potential adjustments [2]

2025年6月12日 ，在首届全球医美科技大会上， "第三届中国整形外科创新转化大赛" 正式启动！ 文末附上报名方法 。欢迎 医疗美容、整形外科相关的项目团队 （企业、医疗机构、高校院所均可）积极参与。 只要提交报名表，就能让全国的顶级医生、投资机构看到您的项目，本身就是一种有效推介 。 一、大赛主题 科技引领整形，创新驱动未来 二、 组织机构和 主办方介绍 主办单位 北京八大处整形医疗科技集团有限公司 中关村医疗器械园有限公司 大赛联合指导单位 中国医学科学院整形外科医院 上海交通大学医学院附属第九人民医院整复外科 吉林大学第一医院整形外科 福建医科大学附属第一医院整形外科 华中科技大学同济医学院附属协和医院整形外科 南方医科大学南方医院整形外科 遵义医科大学附属医院烧伤整形外科 空军军医大学西京医院整形外科 中国人民解放军总医院第四医学中心烧伤整形医学部整形修复科 海军军医大学第一附属医院上海长海医院整形外科 四川大学华西医院整形外科 北京协和医院整形美容外科 北京大学第三医院成形外科 中国技术交易所 三、 大赛组织架构 各分赛区由一位 学术带头人 担任分 赛区主席 并负责组建相应赛区的 组委员会和专家委 ...

Core Viewpoint - The South Korean government has decided to cancel the 10% value-added tax refund policy for medical beauty services starting next year, which may negatively impact the influx of foreign tourists seeking these services [1] Group 1: Policy Changes - The tax refund policy was implemented in April 2016 to promote tourism and attract foreign visitors for medical beauty treatments [1] - Initially intended to last for one year, the policy has been extended multiple times since its inception [1] Group 2: Industry Concerns - Industry insiders express concerns that the cancellation of the tax refund may lead to a decrease in foreign tourists coming to South Korea for medical beauty services [1] - There is a potential risk that some medical institutions may resort to cash transactions with customers, creating a gray area in the industry [1]

Core Viewpoint - AirSculpt Technologies reported a decline in revenue and case volume in Q2 FY2025, but management remains optimistic about achieving its full-year guidance despite ongoing challenges in demand and performance [1][12]. Financial Performance - GAAP revenue for Q2 FY2025 was $44.0 million, down 13.7% year-over-year and below analyst expectations of $45.45 million [1][5]. - Diluted EPS was a loss of $0.01, an improvement from a loss of $0.06 in Q2 2024, but below the expected $0.01 [1][2]. - Adjusted EBITDA decreased to $5.8 million from $6.9 million in the same quarter last year, reflecting a 15.0% decline [1][2]. - Case volume fell to 3,392, a 14.1% decrease from the previous year [2][5]. - Adjusted net income was $1.2 million, down 76.8% from $5.1 million in Q2 2024 [2]. Business Overview - AirSculpt Technologies specializes in minimally invasive body contouring procedures, known for avoiding needles and scalpels, appealing to patients seeking less downtime [3]. - The company operates 32 centers in affluent regions across the U.S., Canada, and the UK, focusing on performance, marketing, and innovation [4]. Operational Highlights - The company noted incremental operational progress, with improvements in revenue decline percentages compared to Q1 FY2025 [1][5]. - Average revenue per case remained steady at approximately $12,975, maintaining the company's premium pricing [5]. - Same-center case volume fell 22.0% in Q2 FY2025, indicating challenges in older locations despite overall company growth [10]. Strategic Initiatives - AirSculpt is piloting new offerings, including a standalone skin tightening procedure and expanded consumer financing options [7]. - The company reported a record increase in patient leads, although conversion rates to booked procedures remain slow [8][9]. Financial Management - Long-term debt was reduced by $16 million during Q2 FY2025, with $8.2 million in cash and no outstanding line of credit, enhancing balance sheet strength [11]. - Operating cash flow for the first half of 2025 was $5.9 million, down from $6.8 million in the same period of 2024 [11]. Future Guidance - The company maintained its full-year 2025 revenue guidance of $160 million to $170 million and adjusted EBITDA target of $16 million to $18 million [12]. - Management expressed cautious optimism about achieving annual guidance, contingent on improvements in case volume and lead conversion [12].